Valneva's 15min chart shows KDJ Death Cross, Bearish Marubozu formation.

Valneva's 15-minute chart has recently exhibited a KDJ Death Cross, accompanied by a Bearish Marubozu at 10/09/2025 15:45. This suggests that the momentum of the stock price is transitioning towards a downward trend, with a potential for further depreciation. Sellers currently dominate the market, and this bearish momentum is likely to persist.

Valneva SE (NASDAQ: VALN) stock experienced a significant drop on September 10, 2025, following the French company's announcement of a delay in the release of Phase 3 Lyme disease vaccine data and a suspension of its IXCHIQ vaccine by the FDA Valneva falls after Lyme disease vaccine data delay, outlook cut^[1]Valneva stock falls after FDA suspension forces guidance cut^[2]. The stock fell by 7% after the news, indicating a shift in market sentiment towards the company.

Valneva initially expected the Phase 3 data to be released in late 2025 but has now pushed the timeline to the first half of 2026. This delay has led to a revision in the company's financial guidance for 2025. Valneva now forecasts annual revenue to be between €165-180 million ($193-210 million), down from the previous €180-190 million forecast. Research and development (R&D) investments have also been cut from €90-100 million to €80-90 million Valneva falls after Lyme disease vaccine data delay, outlook cut^[1]Valneva stock falls after FDA suspension forces guidance cut^[2].

The company cited ongoing uncertainty regarding the FDA's suspension of the IXCHIQ vaccine, which is expected to impact product sales and total revenues. Despite the setbacks, Valneva remains cash flow positive in its commercial business.

To address its financial challenges, Valneva secured a debt facility worth up to $500 million with Pharmakon Advisors, LP. The initial tranche of $215 million will be used to repay existing debt with Deerfield Management Company and OrbiMed, with the remaining $285 million available for future business development. This new financing extends Valneva's debt repayment timeline from Q1 2026 to Q4 2030, offering more favorable terms Valneva stock falls after FDA suspension forces guidance cut^[2].

The Phase 3 clinical trial of Valneva's Lyme disease vaccine candidate, being developed with Pfizer (NYSE: PFE), remains on track. The companies still aim to submit regulatory applications in 2026, with a potential launch in the second half of 2027 pending approval Valneva stock falls after FDA suspension forces guidance cut^[2].

Valneva's stock performance has been further impacted by technical indicators. The 15-minute chart of Valneva's stock exhibited a KDJ Death Cross, accompanied by a Bearish Marubozu on September 10, 2025, at 15:45. This suggests a downward trend in the stock price, with sellers currently dominating the market .